Pharmaceutical Development & Manufacturing
-
Competing In The Rare Disease Space
10/31/2013
Competition has picked up in the rare disease market which is now worth about $10 billion. Russell Basser, senior VP of global clinical research and development at CSL Behring reflects, “The rare disease space is becoming so crowded. We all have to be that much smarter about how we do business and it puts more pressure on drug development.”
-
From Obscurity To Innovation Engine – The Evolution Of Specialty Pharma
10/31/2013
By 2018, it is estimated specialty drug spend will surpass traditional drug spend, and in three years market research project 7 of the top 10 bestselling drugs will be specialty drugs. With such as staggering growth how will insurance companies be able to afford to pay for such lifesaving treatments.
-
The Art Of The Turnaround In Pharma
10/2/2013
Leonard Jacob M.D., Ph.D., a 35-year pharma industry veteran, believes that when assessing a company for growth, although the management team and financials are two common factors to consider, the most important is product opportunity.
-
Teva Explores The Common Ground Of Follow-On And Innovative Pharma
10/2/2013
Teva’s new CEO Jeremy Levin explains the company’s future in “high-value generics” and innovative treatments in CNS, respiratory, and other areas.
-
AstraZeneca Translates 'Winning With Science' From Words To Action
8/29/2013
An exclusive interview with Menelas Pangalos, executive VP of innovative medicines at AstraZeneca, one of the three direct-to-CEO reports, responsible for small-molecule discovery and early-stage (through Phase 2) development.
-
Takeda’s Approach To Becoming A Global Player In The Vaccine Market
7/31/2013
In 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a number of strategic moves, such as the dissolution of the 23-year, 50/50 joint venture with Abbott, known as TAP Pharmaceuticals, and acquiring Millennium Pharmaceuticals (2008) and Nycomed. These changes strengthened Takeda’s position in two of the largest pharmaceutical markets outside of Japan (U.S. and EU), placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?
-
Aptalis — The “Three Ms” Of Specialty Pharma
7/1/2013
Mindset, mission, and model are the self-defined keywords guiding a company that applies its novel delivery technology to new and existing drugs.
-
J&J’s Approach To Drug Discovery And Breakthrough Therapy
7/1/2013
One year ago, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. Its most current version includes a provision that allows sponsor companies to request their drug be designated as a “breakthrough therapy.” In February, Johnson & Johnson (J&J) became only the second company (behind Vertex Pharmaceuticals) to have a drug receive this designation.
-
Companies To Watch: Cempra
6/3/2013
Cempra is one of a rare but expanding breed of companies answering the call for new antibiotics.
-
Companies To Watch: Immune Pharmaceuticals
5/1/2013
Immune Pharmaceuticals is a renewed and broader company as the result of its merger with EpiCept.